Skip to main content

Table 2 Cases of ureteral and renal pelvic HAC in reviewed literatures

From: Hepatoid adenocarcinoma in ureter with next-generation sequencing: A case report and literature review

Case (Reference)

Nationality, year

Age, sex

History of chronic irritation

IHC AFP

Initial AFP (ng/mL)

Initial CEA (ng/mL)

Stage

Treatment

Post treatment AFP (ng/mL)

Outcomes

1 [15]

Japanese (1991)

72, Male

No

+

2246

NA

pT1

Surgery

2.6 (4 months after surgery)

DFS for 10 months, LFU

2 [16]

Japanese (1992)

68, Female

No

+

1220

NA

NA

Surgery

5.0 (2 months after surgery)

DFS for 12 months, LFU

3 [17]

Japanese (2002)

69, Female

No

NA

NA

24.5

pT2

Surgery

NA

DFS for 12 months, LFU

4 [14]

Japanese (2004)

70, Female

Yes

+

24,000

NA

pT2

Surgery and radiotherapy

Normal (4 months after surgery), increased after 9 months

LNM after 9 months, Dead after 28 months

5 [18]

Italian (2011)

80, Female

No

+

NA

NA

pT4

Surgery

NA

NA

6 [19]

Australian (2012)

84, Female

No

+

701

4.2

pT3

Surgery

Normal (5 months after surgery)

DFS for 5 months, LFU

7 [6]

Chinese (2019)

59, Male

Yes

+

64

NA

NA

Surgery

2.5 (1.5 months after surgery)

DFS for 3 months, LFU

8 (our case)

Chinese (2022)

53, Female

Yes

+

569

20.0

pT3

Surgery

22.7 (2 months after surgery)

LNM after 9 months, AWD for 18 months

  1. IHC: immunohistochemical; NA: not available; DFS: disease-free survival; LFU: lost to follow-up; LNM: Lymph node metastasis; AWD: alive with disease